Istodax’s Lymphoma Accelerated Approval Indication Falls Victim To Failed Confirmatory Trial

 
• By Sue Sutter
  
Dangling shoes
BMS' decision to withdraw Istodax's PTCL claim means one less accelerated approval indication dangling in the wind. • Source: Alamy
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Review Pathways

More from Pathways & Standards